Literature DB >> 28799557

The application of an acellular dermal allograft (AlloDerm) for patients with insufficient conjunctiva during evisceration and implantation surgery.

S J Park1, Y Kim2, S Y Jang2.   

Abstract

PurposeTo describe the use of an acellular dermal allograft (AlloDerm) for patients with insufficient conjunctiva during evisceration and implantation surgery.Patients and methodsThe medical records of six patients with insufficient conjunctiva during evisceration surgery were reviewed. It was not possible to close the Tenon's capsule and conjunctiva without wound tension in these patients, so AlloDerm was placed over the sclera, and the edges were sutured with adjacent conjunctiva without tension. The size of the bare AlloDerm graft was measured in all patients. The clinical outcome was the incidence of complications, and the percentage of patients needing additional surgery was also recorded.ResultsThe cause of evisceration was end stage glaucoma (four patients) and endogenous endophthalmitis (two patients). All six eyes of six patients (100%) had a successful outcome showing no complications. Four cases achieved full conjunctivalisation over the bare AlloDerm graft. Two cases had a bare AlloDerm until the last follow-up, but showed no implant exposure. It took a median of 11 weeks for the slow advance of the conjunctival edge to entirely cover the AlloDerm graft.ConclusionsAlloDerm is a promising material for covering sclera and implants in a tension-free manner after evisceration surgery in patients with insufficient conjunctiva.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28799557      PMCID: PMC5770710          DOI: 10.1038/eye.2017.161

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  17 in total

1.  Ophthalmic plastic applications of acellular dermal allografts.

Authors:  P A Rubin; A M Fay; H D Remulla; M Maus
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

Review 2.  Tissue-engineered skin. Current status in wound healing.

Authors:  Y M Bello; A F Falabella; W H Eaglstein
Journal:  Am J Clin Dermatol       Date:  2001       Impact factor: 7.403

3.  Evisceration With Injectable Hydrogel Implant in a Rabbit Model.

Authors:  Irina V Koreen; Elysa A McClintic; Ryan T Mott; Constance Stanton; R Patrick Yeatts
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 May/Jun       Impact factor: 1.746

Review 4.  Complications of hydroxyapatite orbital implants. A review of 100 consecutive cases and a comparison of Dexon mesh (polyglycolic acid) with scleral wrapping.

Authors:  J H Oestreicher; E Liu; M Berkowitz
Journal:  Ophthalmology       Date:  1997-02       Impact factor: 12.079

5.  Acellular dermal matrix (AlloDerm): new material in the repair of stoma site hernias.

Authors:  Karen J Kish; Brian R Buinewicz; Jon B Morris
Journal:  Am Surg       Date:  2005-12       Impact factor: 0.688

6.  Reconstruction of a Long-Segment Tracheal Defect Using an AlloDerm Conduit.

Authors:  William D Bolton; Sharon Ben-Or; Allyson L Hale; James E Stephenson
Journal:  Innovations (Phila)       Date:  2017 Mar/Apr

7.  The porous polyethylene (Medpor) spherical orbital implant: a retrospective study of 136 cases.

Authors:  Sean M Blaydon; Todd R Shepler; Russell W Neuhaus; William L White; John W Shore
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2003-09       Impact factor: 1.746

8.  Use of an acellular allograft dermal matrix (AlloDerm) in the management of full-thickness burns.

Authors:  D J Wainwright
Journal:  Burns       Date:  1995-06       Impact factor: 2.744

9.  Long-term surgical outcomes of porous polyethylene orbital implants: a review of 314 cases.

Authors:  Su-Kyung Jung; Won-Kyung Cho; Ji-Sun Paik; Suk-Woo Yang
Journal:  Br J Ophthalmol       Date:  2011-11-17       Impact factor: 4.638

10.  Higher dose of palonosetron versus lower dose of palonosetron plus droperidol to prevent postoperative nausea and vomiting after eye enucleation and orbital hydroxyapatite implant surgery: a randomized, double-blind trial.

Authors:  Xiao Hu; Fang Tan; Lan Gong
Journal:  Drug Des Devel Ther       Date:  2017-05-15       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.